Skip to main content
TRT
PROVIDER
GUIDE
RESOURCE

Is TRT Worth It? An Honest Look at the Cost, the Evidence, and Who Should Skip It

Decide whether TRT is worth discussing by separating confirmed low testosterone, realistic benefits, fertility plans, risks, monitoring, and the full cost of care.

By TRT Provider Guide

Published 2026-09-18 · Last updated 2026-09-18

Last verified: 2026-09-18

Written and researched by TRT Provider Guide. Editorial research. Not clinically reviewed. Educational information, not medical advice.

Educational resource
Evidence Cited

Is TRT worth it? It can be worth discussing with a clinician when symptoms or signs match, at least two early-morning testosterone tests are consistently low, the cause has been evaluated, and the benefit you care about is realistic. The answer changes fast if fertility matters, the diagnosis is uncertain, or you are expecting TRT to fix vague fatigue by itself.

The key constraint is simple: TRT is not a diagnosis from one number. Current U.S. guidance requires symptoms or signs plus consistently low testosterone, and both the American Urological Association and the Endocrine Society call for repeat early-morning testing.

Here's the part nobody tells you before you swipe a card: there is also an early reassessment point. The AUA says clinicians should discuss stopping testosterone three to six months after treatment begins when testosterone levels normalize but symptoms or signs do not improve.

Best for: a man with properly confirmed low testosterone, matching symptoms or signs, an evaluated cause, and no near-term plan to conceive.

Not for you yet if: you've only had one test, your diagnosis is still unclear, you're trying to have a child soon, or you mainly want a prescription for fatigue, aging, bodybuilding, or performance rather than a medical evaluation.

"Is TRT worth it" has four answers. One of them is yours.

Short answer: Whether TRT is worth it depends first on whether low testosterone has actually been established and whether the problem you want to improve is one TRT can reasonably help. That splits most men asking this question into four groups, and the right next step is different in each one.

Which one are you? Is TRT worth it? Why What to do next
1. Confirmed low testosterone, symptoms/signs match, fertility is not a near-term goal Reasonable to discuss a supervised treatment trial This is the group the major treatment guidelines and trials are meant to address Choose a care route based on diagnosis quality, clinician access, cost, treatment format, and monitoring
2. Symptoms, but never properly tested Unknown — and paying for treatment now can be an expensive mistake Symptoms alone do not diagnose testosterone deficiency Get the recommended diagnostic evaluation first, including repeat early-morning testing
3. Symptoms, but testosterone is not consistently low TRT is harder to justify Fatigue, low mood, low libido, erectile problems, sleep problems, medication effects, thyroid disease, depression, alcohol use, and other conditions can overlap with “low T” symptoms Look for the actual cause with a clinician instead of treating the symptom list as a diagnosis
4. Trying to conceive now or in the near term TRT is usually the wrong starting route Exogenous testosterone can suppress sperm production, and current guidelines advise against testosterone monotherapy when near-term fertility is a goal Start with urology, reproductive urology, endocrinology, or another fertility-aware clinician

There's a fifth situation worth calling out because it is common and easy to miss. In July 2026, the Endocrine Society said that when hypogonadism is properly diagnosed and the only identified cause is overweight or obesity with a BMI above 27, weight loss is typically first-line therapy. That is not a brush-off. It is a clinical answer from the major U.S. endocrine specialty society.

TRT Provider Guide is the independent decision resource for testosterone replacement therapy — helping U.S. adults understand how low testosterone is evaluated, compare online and local care models and providers, and choose the next step that fits their health needs, fertility plans, budget, state, and care preferences, with every material claim verified and dated.

The right TRT provider is not the same for every person — it depends on whether low testosterone has been properly evaluated, your symptoms and health history, your fertility plans, your state, your insurance or cash-pay preference, your treatment-format preference, your budget, and whether online or in-person care is the better starting point. Some situations belong with primary care, urology, endocrinology, reproductive urology, or urgent or emergency care when the symptoms warrant it. Because a general answer cannot resolve those for you, use TRT Provider Guide's Find My TRT Path tool to map your situation to the right care route and the questions to ask before you pay.

→ Not sure which group you are in? Use TRT Provider Guide's Find My TRT Path tool to map the questions and care route that fit your situation.

Who this page is for, and who it isn't

Short answer: This page is for U.S. adult men weighing testosterone replacement therapy for symptoms of low testosterone. It is not written for women, teenagers, transgender or gender-diverse care, athletes chasing performance, or anyone considering testosterone outside of clinician care. The evidence, the risks, and the rules are different for every one of those groups.

You probably got here for one of five reasons. A lab result came back and nobody really explained it. Your partner said something, or didn't say something. A podcast ad found you at eleven at night. A friend "got on it" and now looks like a different person. Or a local clinic quoted you a number that made you close the tab.

None of those are silly reasons to be here. But they're all reasons to search, not reasons to start.

One note before we go further. If you're having chest pain, sudden shortness of breath, a leg that's swollen and painful, or thoughts of hurting yourself, this isn't the page you need right now. Get urgent or emergency care.

How do you know low testosterone is actually the problem?

Short answer: Symptoms alone don't diagnose low testosterone, and one low result shouldn't lead straight to a prescription. The AUA calls for two separate early-morning total testosterone measurements plus symptoms or signs, while the Endocrine Society's July 2026 statement likewise calls for at least two early-morning fasting tests and accurate measurement. Getting this step right is the single highest-value thing you can do before spending a dollar.

Here's what makes this harder than it sounds.

Your testosterone changes through the day. That's why the major guidelines emphasize early-morning testing. The AUA makes two separate early-morning measurements a Strong Recommendation with Grade A evidence.

It changes between draws, too. The AUA notes meaningful within-person variation and recommends repeat measurement rather than treating one result as a diagnosis. One number is a snapshot in bad lighting.

And the lab method can matter. In its July 2026 statement, the Endocrine Society said non-standardized testosterone assays can produce meaningfully different results. It points to CDC Hormone Standardization (HoST)-certified assays as a way to improve comparability across laboratories.

That's a useful question to ask: "Is this testosterone assay standardized or CDC HoST-certified?" It will not diagnose anything by itself, but it can reduce avoidable measurement uncertainty.

About that 300 ng/dL number

You'll see 300 ng/dL everywhere. It's real, but it's narrower than the internet makes it sound.

The AUA uses total testosterone below 300 ng/dL as a reasonable cut-off in support of a diagnosis. Not as the diagnosis. Its guideline says testosterone deficiency requires low testosterone and symptoms or signs, based on two early-morning measurements on separate occasions.

The Endocrine Society's July 2026 statement adds that the definition of hypogonadism is the same at any age and warns that labels such as "age-related," "late-onset," and "functional" hypogonadism can blur the line between disease and normal aging.

One small conflict worth knowing about. The Endocrine Society's 2026 statement says at least two early-morning fasting tests. The AUA guideline does not make fasting a universal requirement. Practical translation: go early in the morning, follow your clinician's instructions about fasting, and use a reliable laboratory method.

Rule out the obvious competing causes first

The Endocrine Society is direct about this: low energy, low libido, and low mood have many causes. Clinicians should look for reversible contributors, including obesity and medication effects such as corticosteroid or opioid use.

Sleep apnea, alcohol use, thyroid disease, depression, and iron deficiency can also produce overlapping symptoms. If one of those is driving the problem, testosterone may not be the answer.

→ Not sure whether testing or treatment comes first in your case? Find My TRT Path maps your situation to the right care route and the questions to ask before you pay anyone.

What does TRT actually do, and what does it not do?

Short answer: In men with genuinely low testosterone, the strongest evidence is for sexual desire and sexual activity, with smaller real effects on mood, lean body mass, bone density, and anemia. The evidence is weakest for the two things TRT is advertised for most — energy and general quality of life. Nothing in the randomized evidence supports it as heart protection, diabetes prevention, brain fuel, or anti-aging.

This table is the heart of the page. It's what we'd want if we were the one holding the credit card.

What men hope for What the best trials found The actual number What the AUA tells clinicians to say Our read
Sex drive The Testosterone Trials (790 men, 65+, NEJM 2016) and the TRAVERSE Sexual Function Study (1,161 men with low libido, 2 years, JCEM 2024) both found real gains T-Trials sexual desire treatment effect 2.93 (95% CI 2.13–3.74) May improve low sex drive One of the best-supported symptomatic benefits. If low sexual desire is a major complaint and testosterone deficiency is properly established, the evidence is stronger here than for vague fatigue
Erections Here the two big trials disagree. The T-Trials found improvement. TRAVERSE's two-year study of men with low libido found improved activity, symptoms, and desire — but not erectile function T-Trials IIEF effect 2.64 (95% CI 1.68–3.61); TRAVERSE found no significant erectile difference May improve erectile function Modest at best, and not reliable. TRT is not an ED drug. Many men need both, or need the erection problem worked up separately
Mood and depressive symptoms T-Trials PHQ-9 effect −0.27; negative mood −0.49 May improve depressive symptoms Small but consistent. Not a replacement for treating depression
Energy, vitality, fatigue The trial built specifically to test vitality missed its main endpoint Fatigue score effect 1.21 (95% CI −0.04 to 2.46), p=0.06 "Evidence is inconclusive" for energy, fatigue, and quality of life The gap between the ads and the data. "More energy" is the number one marketing promise and the weakest claim on this table
Walking, physical function T-Trials No significant difference on the main measure (p=0.20); only reached significance when all three trials were pooled (20.5% vs 12.6%) — Weak. Don't buy TRT to walk further
Muscle and fat Review of the trial literature (Saad 2011) Changes in fat mass, lean mass, and strength show up at 12–16 weeks and settle between 6 and 12 months May improve lean body mass Real and gradual. Heavily dependent on what you do in the gym and kitchen
Bone density T-Trials bone study Density and estimated strength improved May improve bone mineral density It improves the measurement. Then read the next row
Fewer broken bones TRAVERSE fracture substudy (5,204 men, ~3.5 years, NEJM 2024) Fractures were more common on testosterone: 91 men (3.50%) vs 64 (2.46%) on placebo. Investigators expected the opposite — The finding almost nobody publishes. Better bone density did not turn into fewer fractures. If you have osteoporosis, raise this before you start
Anemia T-Trials anemia study; TRAVERSE Corrected anemia more often than placebo in men who had it May improve anemia Real, and a legitimate medical reason to treat
Preventing diabetes TRAVERSE diabetes substudy Risk of progressing from prediabetes to diabetes did not differ meaningfully Evidence inconclusive on measures of diabetes Don't buy TRT as metabolic insurance
Sharper thinking T-Trials cognition study No benefit on memory or cognitive measures Evidence inconclusive on cognitive function No
Heart protection TRAVERSE (5,246 men with heart disease or high risk, NEJM 2023) Major cardiac events 7.0% vs 7.3% placebo, hazard ratio 0.96 — non-inferior, not protective Cannot be stated definitively whether TRT raises or lowers cardiovascular risk TRAVERSE was a safety result, not a benefit result. Any page selling TRT as heart protection is over-reading it
Longevity, anti-aging No randomized evidence supports TRT as a general anti-aging treatment — FDA's current information says approved testosterone products are for men with low testosterone plus an associated medical condition; FDA requested removal of the prior age-related limitation-of-use statement in June 2026 No. Do not turn a medical treatment for testosterone deficiency into a general anti-aging promise

Read that table twice if you need to. The honest summary is this: TRT is a specific tool for a specific problem, and it works best when you can name the problem.

The sentence that should change how you think about this

The AUA guideline tells clinicians to inform patients that "the evidence is inconclusive whether testosterone therapy improves cognitive function, measures of diabetes, energy, fatigue, lipid profiles, and quality of life measures."

Energy. Fatigue. Quality of life. Those are the three words in every ad you've seen.

That doesn't make TRT a bad decision. It makes it a narrow one. If your level is genuinely low and your main problem is one of the outcomes that trials have actually measured, you are closer to the population in which benefit has been demonstrated. If your level is normal and your complaint is fatigue, you're not — and you'd carry the same risks with none of the upside.

Knowing which of those you are is worth more than any provider comparison on the internet.

What makes the case stronger, and what makes it weaker?

Short answer: The same treatment can be a good decision for one man and a poor one for his neighbor. These are the specific factors that move the needle in each direction, drawn from the diagnostic standards and trial populations above.

Makes TRT more likely to be worth discussing Makes it weaker, or points you somewhere else
Two or more low early-morning tests on a standardized assay One result, wrong time of day, or an unknown lab method
Symptoms that match — low sex drive, low mood, anemia, loss of lean mass Vague fatigue with several plausible other causes
Someone has actually looked for why your level is low Nobody has investigated the cause
A known cause involving the testicles, pituitary, or hypothalamus BMI over 27 with no other cause identified — weight loss is typically first-line here
You're comfortable with ongoing labs and follow-up You want a one-time fix and no further appointments
Fertility isn't a near-term goal You're trying to conceive, or plan to within a couple of years
You want realistic gains, not guaranteed ones Your goal is guaranteed muscle, fat loss, or feeling 25 again
The cost works for you at year three, not just month one The math only works at an introductory price

What does a year of TRT actually cost?

Short answer: There is no honest national “all-in” price for TRT through insurance, because deductibles, copays, laboratory coverage, prior authorization, visit frequency, drug choice, and pharmacy pricing vary by plan. Online cash-pay programs are easier to model from public prices, but even there a published starting price is not the same thing as a complete first-year bill.

Affiliate disclosure: TRT Provider Guide has affiliate relationships with Male Excel and Taurus Meds. Those relationships do not decide what we publish or which care route we describe as the better fit. The provider links in this article are internal research links unless a verified partner destination is clearly identified on the destination page.

Public prices below were checked on 18 September 2026. They are published-price models, not patient quotes.

Care route Published starting inputs What can be calculated What remains unknown
Your own doctor + insurance Your plan's visit, lab, pharmacy, deductible, coinsurance, and prior-authorization rules No defensible national all-in total Your actual benefit design, required labs, product, pharmacy, and visit schedule
Cash-pay local care + retail pharmacy Clinician, lab, and pharmacy cash prices vary by location and product No defensible national all-in total The exact diagnosis workup, prescription, monitoring schedule, pharmacy price, and follow-up fees
Male Excel $99 online consultation; $99/month required Medical Membership; dedicated pricing page lists injectable testosterone cypionate with thyroid from $120/month and cream with thyroid from $132/month; shipping extra $2,727 + shipping for 12 months at the published injection starting price: $99 + 12×$99 + 12×$120 Dose-related price changes, shipping, any extra testing, and which current public “starts at” figure applies to your offer
Hone Health Plus $65 assessment; $135/month Plus membership; testosterone injections from $28/month; current membership materials say an additional confirmatory test may be required $2,021 using $65 + 12×($135+$28), before any confirmatory-test charge or higher medication price Confirmatory-test cost, final medication dose/price, state access, and any extra services
Taurus Meds $49 intake is live on the current site; company-issued materials describe $149/month with a six-month commitment and $199 month-to-month $1,837 if the $149 rate applies for all 12 treatment months; $2,437 if $199 applies for all 12 months, each plus the $49 intake Whether those recurring prices are the current checkout terms, whether a separate fee in the Terms applies, later lab charges, exact product, and final commitment

The line that changes the question

A published medication price is only one line in a TRT bill.

What you are usually paying for is a care system: diagnostic testing, clinician time, monitoring, refills, medication fulfillment, and support. That can be worth money. It can also be overpriced for your situation.

The useful comparison is not “Which vial is cheapest?” It is:

  • What does the first year cost under my insurance or cash-pay route?
  • What testing is required before treatment?
  • What testing is included later?
  • Who reviews abnormal results?
  • What exact product would I receive?
  • Is it FDA-approved or compounded?
  • Which pharmacy fills it?
  • What happens if treatment does not help enough to continue?

Three things the public pricing pages make easy to miss

Male Excel's dedicated pricing page bundles thyroid medication into its advertised injectable and cream packages. Thyroid medication is a separate prescription treatment. The current Male Excel homepage also advertises testosterone therapy “starting at $99/month,” while the dedicated HRT cost page lists the injectable package from $120/month plus the $99 membership. Treat the model above as a dated subtotal and get the exact written quote for your plan.

Male Excel's oral Triclozene option is not testosterone. Its pricing page describes Triclozene as clomiphene citrate with thyroid ingredients. Clomiphene is a selective estrogen receptor modulator, not testosterone replacement therapy.

Taurus Meds publishes a $49 intake offer, but its recurring-price documents are not fully reconciled. Current TRT Provider Guide checks found a $149/month offer, a separate company-issued $199 month-to-month figure, and a possible fee clause in the Terms. Do not call any one subtotal a complete bill until checkout resolves the conflict.

What about insurance?

Coverage depends on the plan, diagnosis, product, pharmacy benefit, and prior-authorization rules. Do not assume that “TRT is covered” means your preferred formulation, compounded preparation, laboratory schedule, or online program is covered.

If your priority is a specific FDA-approved product through insurance, start with the clinician and pharmacy path your plan actually covers rather than using a compounded cash-pay program as the default.

→ Want the detailed price math? See our Taurus Meds cost analysis and Hone Health TRT cost and testing review, or use Find My TRT Path if you are still deciding between insurance, cash-pay, local, and online care.

Online program or your own doctor?

Short answer: If you have a clinician who will evaluate the problem and your insurance covers the care you need, local or in-network care may cost less. Online programs can reduce travel and scheduling friction, but they do not remove the need for a real diagnosis, a valid prescription, state-authorized care, appropriate monitoring, or a clear answer about whether the product is FDA-approved or compounded.

What the guideline says about compounded testosterone

The AUA guideline says commercially manufactured testosterone products should be prescribed rather than compounded testosterone when possible. That is a Conditional Recommendation with Grade C evidence — guidance, not a ban.

Compounded preparations are not FDA-approved finished drug products. They are not generics of an approved testosterone product, and they should not be described as “the same,” safer, more natural, or proven equivalent unless a narrow claim is specifically supported.

That does not make every compounded prescription inappropriate. It means the reader should know what exact product is being prescribed and which pharmacy will dispense it.

The damaging admission about online testing

Both the AUA and the Endocrine Society call for repeat early-morning testosterone measurements before diagnosing testosterone deficiency.

The public documents do not support one blanket statement about all three online programs:

  • Male Excel publicly describes an at-home testing path, but its pages reviewed here do not establish that every new patient completes two separate early-morning diagnostic measurements before prescribing.
  • Hone's current membership materials explicitly say an additional confirmatory test may be required for men starting testosterone therapy.
  • Taurus publicly describes a $49 LabCorp/Quest intake panel, but the public offer reviewed here does not establish the full repeat-test sequence for every patient.

So the right conclusion is not “online programs only do one test.” The accurate conclusion is: do not assume the diagnostic sequence from a marketing page. Ask what repeat testing is required in your case before a prescription decision.

If you already have two appropriate morning results, bring them. If you do not, ask the clinician how the program will establish the diagnosis before treatment.

If you've decided the online route fits, what should you compare?

We have not enrolled in, purchased from, or tested the cancellation process of these programs. This is a public-document comparison, not a hands-on review.

Male Excel publishes a $99/month Medical Membership with unlimited messaging and e-visits, a $99 consultation, and testosterone packages priced separately. It also publicly describes compounded testosterone and thyroid-containing package options. Its FAQ currently lists 11 states it does not serve.

Hone Health publishes Plus at $135/month and Premium at $155/month, with medication separate. Its current help center says confirmatory testing may be required before testosterone therapy and publishes different lab schedules by membership tier.

Taurus Meds publishes a $49 intake with LabCorp or Quest and clinician review. Its recurring-price documents and fee terms need to be reconciled before calling the program's first-year cost complete.

Those facts are enough for a care-model comparison, but not enough for a universal provider winner on a page whose primary question is whether TRT itself is worth pursuing.

→ Already past the treatment decision and comparing providers? Read our provider-specific research, including Male Excel eligibility and access, Hone Health TRT reviews and cost, and Taurus Meds cost.

→ Still weighing local care against an online program? Use Find My TRT Path to map the care-route questions that matter before you pay.

What are you actually risking?

Short answer: One of the clearest monitoring issues with testosterone is erythrocytosis — a rise in red blood cells reflected by hematocrit. The AUA says to investigate a baseline hematocrit above 50% before treatment and to intervene if hematocrit reaches 54% or higher during therapy. FDA also requires class-wide blood-pressure warnings for testosterone products.

A quick definition, since these terms come up on lab reports. Hematocrit is the percentage of your blood made up of red blood cells. PSA is prostate-specific antigen, a blood marker used in prostate-cancer screening decisions. Spermatogenesis is sperm production.

Risk or monitoring issue What the evidence shows What this means for the decision
Higher hematocrit / erythrocytosis The AUA requires baseline hemoglobin/hematocrit assessment; a baseline hematocrit above 50% calls for evaluation, and an on-treatment hematocrit of 54% or higher warrants intervention This is one reason TRT requires follow-up rather than a one-time prescription
Higher blood pressure FDA required class-wide blood-pressure warnings after ambulatory blood-pressure studies found increases across testosterone products Blood pressure belongs in the risk discussion, especially when hypertension is already present
Atrial fibrillation signal in TRAVERSE Atrial fibrillation occurred more often in the testosterone group than placebo in TRAVERSE This was a safety signal, not proof that every patient has the same risk
Pulmonary embolism signal in TRAVERSE Pulmonary embolism occurred more often in the testosterone group; the Endocrine Society's 2026 statement highlighted the signal Prior clotting history or new clot symptoms deserve clinician attention rather than reassurance from a marketing page
Acute kidney injury signal in TRAVERSE Acute kidney injury occurred more often in the testosterone group in that trial It is part of the trial's safety context, not a prediction for an individual
Fractures In the TRAVERSE fracture substudy, clinical fractures occurred in 3.50% on testosterone versus 2.46% on placebo Better bone-density measures did not translate into fewer fractures in that trial
Prostate questions Long-term prostate safety remains an area of active evidence review; FDA requested label revisions in June 2026 Do not treat old prostate warnings or new reassuring headlines as the whole story
Transfer from gels or creams Topical testosterone products can expose other people through skin contact Follow the exact product label and clinician instructions for the product prescribed
Suppressed sperm production Exogenous testosterone can suppress gonadotropins and spermatogenesis Fertility plans can change the care route before treatment starts

Some situations call for a more careful in-person or specialist evaluation before an online intake should be the focus, including major diagnostic uncertainty, fertility concerns, elevated hematocrit, suspected pituitary or testicular disease, or other complex medical history. The Endocrine Society also lists conditions in which it recommends against starting testosterone therapy, including near-term fertility and certain uncontrolled or high-risk clinical situations.

Does TRT make you infertile?

Short answer: Testosterone taken from outside the body switches off the signal that tells your testicles to make sperm. In male contraceptive trials, exogenous testosterone suppressed sperm production substantially; in one World Health Organization study, 65% of healthy men reached azoospermia within six months. Most men recover after stopping — but "most" is not "all," and the AUA tells clinicians not to prescribe testosterone to men who are currently trying to conceive.

Here's the mechanism in plain terms. Your brain sends a hormone signal down to your testicles telling them to produce both testosterone and sperm. When you add testosterone from outside, your brain reads the level as high and stops sending the signal. Testosterone in your blood goes up. Testosterone inside the testicle, which is what sperm production actually needs, goes down. Sperm production falls with it.

This effect is so reliable that researchers studied testosterone as a male contraceptive. In a World Health Organization multicentre trial, 65% of healthy men reached zero sperm within six months on weekly injections.

Recovery, from the best available data: a meta-analysis of 30 contraceptive trials found that after stopping testosterone, about 67% of men were back above 20 million sperm per mL at six months, 90% at twelve months, and 100% at twenty-four.

Now the honest limits on those numbers. Those men were healthy volunteers in controlled trials, on defined doses for defined periods. Real-world recovery can be slower. In one study of men treated to restore fertility after testosterone use, 30% of 66 men had still not reached a total motile count above five million after twelve months on a recovery protocol.

So: we will not tell you TRT makes you infertile. We will not tell you your fertility will come back on any timeline. Nobody honest can tell you either of those things. What we can tell you is that this is a real and significant effect, the guideline says don't start while you're trying to conceive, and this decision belongs with a specialist before it belongs with a telehealth intake form.

If children are still on the table, ask a urologist or reproductive urologist about fertility planning, which can include semen testing or sperm banking and, in selected men, medications that stimulate endogenous testosterone rather than replacing it. The AUA/ASRM male-infertility guideline says clinicians may use aromatase inhibitors, hCG, selective estrogen receptor modulators, or combinations in infertile men with low testosterone. Those are not TRT. They are not interchangeable with it, and nobody should be calling them "natural TRT."

→ If kids are still a possibility, don't start with a general online program. Find My TRT Path will point you toward a fertility-aware care route and the questions to bring to that appointment.

Are you on TRT for life?

Short answer: TRT should be approached as potentially long-term treatment when the underlying reason for low testosterone is persistent and the treatment is helping. But “once you start you can never stop” is too absolute. The AUA says clinicians should discuss stopping testosterone three to six months after treatment begins when testosterone levels normalize but symptoms or signs do not improve.

That's the off-ramp most consumer pages miss.

Older U.S. claims studies found high discontinuation rates after testosterone was started, including particularly low persistence with topical therapy. Those studies tell us that many men stopped filling treatment; they do not tell us why. They cannot prove that men were misdiagnosed, that treatment failed, or that stopping was medically appropriate.

A useful way to frame the first months is this: agree on the problem you are trying to improve, then schedule a real reassessment. If testosterone reaches the intended range but the target symptoms or signs do not improve, the AUA says the clinician should discuss cessation.

If you and your clinician decide to stop, make that a supervised decision. What happens afterward depends on the underlying condition, treatment duration, formulation, fertility goals, and individual recovery; no article can promise a specific recovery timeline.

How long before you know if it's working?

Short answer: There is no reliable week-by-week promise for how you will feel on TRT. An older review found that different outcomes can begin on different timelines, but response varies by symptom, formulation, baseline condition, and individual biology. The more reliable production rule is the AUA's three-to-six-month reassessment when testosterone normalizes but symptoms or signs do not improve.

Older literature has reported approximate patterns such as earlier changes in sexual interest and later changes in body composition. Treat those as rough research observations, not a countdown clock.

Timepoint Useful question
First weeks Are there side effects, blood-pressure issues, or practical problems with the treatment format?
Early follow-up Did the clinician confirm the laboratory response at an appropriate time for the formulation?
Ongoing follow-up Are hematocrit and other clinically indicated monitoring items being checked?
3–6 months If testosterone is in the intended range but the target symptoms or signs have not improved, should treatment continue?

Five questions to settle before you pay anyone

Most people are bad at remembering exactly how they felt months ago. That makes vague goals easy to move.

  1. What exact problem are we trying to improve? “Feeling better” is not a specific target.
  2. How will we know if it improved? Agree on what matters before treatment changes your expectations.
  3. What gets monitored, and how often? Ask for the plan rather than assuming every program uses the same schedule.
  4. When do we reassess? Put the follow-up on the calendar.
  5. What happens if my testosterone goes up but the problem does not improve? The answer should not be “keep paying forever.”

You can keep a simple note of the symptoms or problems you care about and bring it to follow-up. Do not use a self-score as a diagnosis or as a substitute for the clinician's evaluation.

→ Want a question list to bring to a visit or intake? Find My TRT Path builds the next-step questions around your situation.

What should you try instead, or first?

Short answer: If testosterone is not consistently low, or the diagnosis is not established, the next move is usually to look for competing causes rather than treating a symptom list as proof of testosterone deficiency. Some reversible contributors can affect both testosterone levels and the same symptoms that make people search for TRT.

The one with a current Endocrine Society statement behind it: if hypogonadism is properly diagnosed and the only identified cause is overweight or obesity with a BMI above 27, the Society said in July 2026 that weight loss is typically first-line therapy.

Sleep apnea can mimic part of the picture. Fatigue, low mood, poor sleep, and sexual symptoms can overlap with what people call “low T.” If you snore heavily, wake unrefreshed, or someone has noticed pauses in your breathing, that is worth raising with a clinician.

Other competing or reversible contributors can include: alcohol use, opioid medications, corticosteroids, thyroid disease, depression, iron deficiency, and other conditions identified during evaluation.

Over-the-counter “testosterone boosters”: these are supplements, not TRT. They are not FDA-approved testosterone-replacement drugs.

Clomiphene, enclomiphene, and hCG are not TRT. Clomiphene is used off-label in men in some fertility or testosterone-management settings. Enclomiphene is not FDA-approved as a marketed drug for male hypogonadism. hCG is different again: FDA-approved hCG products have male indications that include selected cases of hypogonadotropic hypogonadism, and the AUA/ASRM male-infertility guideline discusses hCG, SERMs, and aromatase inhibitors as fertility-aware alternatives in selected men. None should be called “natural TRT,” and they are not interchangeable with exogenous testosterone.

Worth knowing: Male Excel's oral Triclozene product is described by the company as clomiphene citrate with thyroid ingredients. Whatever the marketing heading says, that is not testosterone replacement therapy.

What's changing in 2026, and what hasn't

Short answer: Testosterone policy and labeling really did change in 2025–2026, but several older statements in the search results are now stale. FDA removed the prior cardiovascular boxed-warning language in 2025, requested additional label changes in June 2026, and is exploring a possible new indication. Testosterone is still a Schedule III controlled substance, and the temporary federal telemedicine extension still expires on December 31, 2026 unless replaced or extended.

Changed, February 2025: FDA removed boxed-warning language about increased major cardiovascular outcomes after reviewing TRAVERSE and required class-wide blood-pressure warnings.

Changed again, June 2026: FDA requested updates to testosterone prescribing information that include removing the prior limitation-of-use statement about age-related hypogonadism and revising information related to prostate cancer and benign prostatic hyperplasia. That means a page that still says FDA “retains the age-related limitation” is out of date.

Not the same as a new approved indication: FDA's current testosterone information still says approved products are indicated for men with low testosterone tied to an associated medical condition. In April 2026, FDA encouraged sponsors to contact the agency if they wanted to pursue a potential new indication for low libido in men with idiopathic hypogonadism. A potential indication is not an approval.

What has not changed: as of September 2026, testosterone remains a Schedule III controlled substance and still requires a valid prescription.

The rule with a real expiration date: HHS and DEA extended the federal telemedicine flexibilities for prescribing controlled medications through December 31, 2026. Those flexibilities allow qualifying DEA-registered practitioners to prescribe Schedule II–V controlled substances by telemedicine without a prior in-person evaluation when the required conditions are met. State law, practitioner licensure, legitimate-medical-purpose requirements, and other applicable rules still matter.

We're telling you that as context, not as pressure. Nothing about a temporary rule should make you rush a medical decision.

What we actually verified

Verification date: 18 September 2026

Read directly from primary or official medical/regulatory sources: the AUA Testosterone Deficiency guideline, currently listed by AUA as the 2018 guideline with validity confirmed in 2024; the Endocrine Society's 16 July 2026 statement and testosterone-therapy guideline resources; FDA's February 2025 class-wide labeling action; FDA's current Testosterone Information page and June 2026 requested labeling updates; FDA's April 2026 notice about a possible future low-libido indication; DEA's current controlled-substance schedules; and the HHS/DEA telemedicine extension through 31 December 2026.

Read directly from provider pages: Male Excel's $99 consultation, $99 monthly Medical Membership, dedicated pricing-page starting prices, thyroid-containing package language, Triclozene ingredient description, cancellation language, and state-exclusion list; Hone Health's $65 assessment, $135 Plus and $155 Premium tiers, medication starting prices, and statement that an additional confirmatory test may be required for men starting testosterone; Taurus Meds' live $49 blood-test/consult offer and LabCorp/Quest language.

Provider-stated or document-derived, not independently tested: all provider prices, what an individual patient would be charged, clinician access, testing fulfillment, shipping, pharmacy fulfillment, support quality, cancellation experience, and whether a published program workflow happens exactly as described for every patient.

Commercial facts we narrowed rather than pretending were complete: Taurus recurring-price figures come from public company-issued materials and conflict with other terms that may apply at purchase; Male Excel has conflicting public “starts at” language across pages; Hone's final first-year bill depends on confirmatory testing and medication price. The cost table therefore labels these as published-price models, not complete patient bills.

Could not be established from public pages for every program: the complete repeat-test process for every patient, the exact finished testosterone product a future reader would receive, every assigned dispensing pharmacy, every current clinician license, and a complete state-by-state access map across all programs.

Not evaluated hands-on: we have not enrolled in, purchased from, received medication from, or tested the cancellation process of any program named here. This is a public-document decision guide, not a hands-on review.

How we produced this page: we checked the primary guidelines, FDA/DEA/HHS materials, major trial publications, and provider documents dated above, then separated verified facts, provider-stated facts, and editorial conclusions. Commercial claims are evaluated under How We Review TRT Providers. The care-route conclusions on this page are editorial judgments based on those sources. They are not a diagnosis and do not replace a clinician who can evaluate you.

Frequently asked questions

Is TRT worth it if my testosterone is 350?

A single value of 350 ng/dL cannot answer that. The AUA uses below 300 ng/dL as a reasonable cut-off in support of diagnosis, but diagnosis also requires symptoms or signs and two early-morning measurements. The Endocrine Society likewise emphasizes consistently low, accurately measured testosterone rather than diagnosing from one number.

Is TRT worth it just for energy?

That is a weaker case than the advertising makes it sound. The Testosterone Trials' vitality study missed its primary endpoint, and the AUA says evidence is inconclusive for energy, fatigue, and quality-of-life measures. If fatigue is the main complaint, competing causes deserve a real evaluation.

How much does TRT cost per month?

There is no reliable national all-in monthly price. Insurance costs depend on your plan, clinician, tests, drug, pharmacy, deductible, and prior authorization. Online programs publish clearer starting prices, but membership, medication, confirmation tests, dose changes, shipping, and follow-up can change the actual bill.

Is online TRT legit?

Legitimate telehealth care exists, but online does not mean automatic. Testosterone is Schedule III, requires a valid prescription, and must be prescribed by an authorized clinician for a legitimate medical purpose under applicable federal and state rules. A questionnaire does not guarantee approval.

Does TRT shrink your testicles?

Exogenous testosterone can suppress the hormone signals that support testicular testosterone production and spermatogenesis, and testicular volume can decrease. Fertility plans should be discussed before treatment rather than after.

Can I use my HSA or FSA for TRT?

Some provider expenses and eligible prescription or laboratory costs may qualify, and Male Excel states that its listed treatments are FSA/HSA eligible. Eligibility depends on the expense and your plan, so check your administrator rather than assuming every membership or add-on qualifies.

Will insurance cover TRT?

Sometimes. Coverage depends on your diagnosis, plan criteria, prior authorization, formulary, product, pharmacy, and testing requirements. Do not assume a compounded cash-pay preparation is covered because an FDA-approved testosterone product might be.

Is TRT worth it at 40? At 50? At 60?

Age alone does not decide it. The Endocrine Society's 2026 statement says the diagnostic definition is the same at any age: symptoms consistent with low testosterone plus consistently low, accurately measured testosterone.

Does TRT fix erectile dysfunction?

Not reliably. The Testosterone Trials found a modest improvement in erectile-function scores, while the TRAVERSE sexual-function substudy found improved sexual activity and desire but not erectile function. Low libido and erectile dysfunction overlap, but they are not the same problem.

What's the cheapest legitimate way to do TRT?

There is no universal cheapest route because insurance and local cash prices vary. If you have coverage and a clinician willing to manage the condition, an in-network route may be less expensive than a bundled online cash-pay program. Compare the complete year, not one teaser price.

Is TRT worth it if I'd be on it forever?

Treat “forever” as the wrong first question. Ask what problem treatment is meant to improve and when it will be reassessed. The AUA says clinicians should discuss cessation at three to six months when testosterone normalizes but symptoms or signs do not improve.

What happens if my testosterone goes up but I still feel bad?

That is exactly when the original diagnosis, competing causes, treatment goals, side effects, and continued value of therapy need to be reassessed. The AUA specifically calls for a cessation discussion at three to six months when testosterone normalizes without symptom or sign improvement.

Sources

Educational notice: This page provides educational information. It does not diagnose low testosterone, interpret your personal lab results, determine whether TRT is appropriate for you, or replace care from a licensed clinician. Testosterone is a Schedule III controlled substance in the United States and requires a valid prescription. Prices, policies, state access, products, and federal telemedicine rules can change; the verification date above tells you when we last checked. If you have chest pain, sudden shortness of breath, a painful swollen leg, or thoughts of harming yourself, seek urgent or emergency care now.

Still not sure which TRT care route fits you? Use our free Find My TRT Path tool.

Ready to explore your options?

Our tool helps you narrow down the care route that fits your situation based on testing, budget, and fertility goals.

Find My TRT Path

Not sure which TRT route fits you?

Find My TRT Path